Benign Prostatic Hypertrophy Clinical Trial
— PRECOCEOfficial title:
Study ¨PRECOCE Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours
NCT number | NCT02401581 |
Other study ID # | 14-PP-07 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 2, 2015 |
Est. completion date | June 8, 2021 |
Verified date | September 2021 |
Source | Centre Hospitalier Universitaire de Nice |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Benign hypertrophy of the prostate (BPH) is the most frequent pathology in the urinary tract of middle-aged men. In recent years, to enable BPH treatment with larger volumes and to reduce the risk of hemorrhage known to be associated to the transurethral resection of prostate treatment, transurethral photovaporisation of the prostate (PVP ) with the GreenLight (GL) XPS 180 W was developed. Therefore, the question arises to maximally reduce the length of catheterization to facilitate outpatient surgical management of prostate adenoma. In the investigators study, the investigators propose to evaluate the failure rate of an early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS in selected patients on general anesthesia or spinal anesthesia. To this end, the investigators realize a national multicenter prospective study including 300 patients. The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours.
Status | Completed |
Enrollment | 200 |
Est. completion date | June 8, 2021 |
Est. primary completion date | August 21, 2019 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 45 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. patients with lower urinary tract symptoms (LUTS ) 2. IPSS= 15 despite medical treatment > 1 month if monotherapy or > 3 months if bitherapie OR acute urinary retention ( RAU ) non-medical after the 1st failure to remove the catheter OR acute prostatitis OR macroscopic haematuria of prostatic origin 3. prostate volume > 30 cc by transrectal ultrasonography ; 4. IPSS Qol = 3 has at inclusion ; 5. PSA = 4 ng / ml ; 6. if PSA between 4 and 10 then PSA L/T =25 % or negative PBP <6 months . 7. Accommodation <50 km; 8. company available for the return at home and monitoring first post- operative night . 9. patient sign the informed consent 10. patient covered by social security or other health insurance Exclusion criteria 1. post- voiding residue > 250 cc by suprapubic ultrasound not older than < 45 days 2. prostate volume > 100 cc by transrectal ultrasound not older than 45 days 3. urological antecedents : o urethral stenosis or cervical disease - UTI in progress - SAD patient or self-catheterization - obstructive hydronephrosis + / - renal failure - vesical calculi - cancer of the prostate treated or untreated - bladder tumor associated - Interstitial cystitis ( symptom or biopsy) 4. antecedent of the prostate surgery 5. neurologic bladder ( parkinsonian syndrome , multiple sclerosis , lupus, neuropathy, Diabetic, cauda equina syndrome ) 6. criteria related concomitant medications that can not be stopped at least < 48 hours before PVP with GL XPS 180 W 7. contra indication for outpatient care for medical reason 8. contra indication of a product analgesic according to protocol 9. patient inability to understand and sign the informed consent as well as completing the questionnaires 10. ASA Score > 3 . |
Country | Name | City | State |
---|---|---|---|
France | CHU Brest Urologie | Brest | |
France | CH Grasse - urologie | Grasse | Alpes-maritimes |
France | CHU Grenoble | Grenoble | |
France | CHU Limoges -Urologie - Hôpital Dupuytren | Limoges | |
France | APHM - Urologie - Hôpital Conception | Marseille | Paca |
France | CHU de Nice - Urologie | Nice | Alpes-Maritimes |
France | AP-HP - Urologie Hôpital Tenon | Paris | Ile De France |
France | Institut Mutualiste Monsouris urologie | Paris | Ile De France |
France | Polyclinique les Bleuets | Reims | |
France | CHU Rennes | Rennes | |
France | CH privé St Brieuc | Saint-Brieuc | Cote D'armor |
France | CHRU Tours | Tours | Vendée |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nice |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | failure rate of a limited catheterization duration of 3 hours post- operative | • The failure rate of a limited catheterization duration of 3 hours post- operative is defined by a need of recatheterizatrion within 24 hours post- GL with PVP XPS 180W . The catheterization remains indicated in case of macroscopic hematuria RAU or if no natural urination is possible | at three hours post surgery | |
Secondary | Total dose of energy | The total dose of energy delivered to the tissue induring the intervention will be expressed and collected by means of the instrumentation of the GL-XPS console. | during 24 hours hospitalisation | |
Secondary | The duration of recatherization | The duration of recatherization is regarded as the total cumulative duration of catheterization regardless of the number of attempts for removale when it is a failure. The average duration of resondage counts only recatheterizations occurring in the first week which may be considered as due to PVP with GL XPS 180W followed by a shortened catheterization of 3 hours post- operatively . The duration of recatherization is defined from the time when it was done in thefirst week post- operative until urinary recovery | during 24 hours hospitalisation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02509975 -
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
|
N/A | |
Completed |
NCT01177436 -
Prostate Cancer Antigen 3 (PCA-3) Gene Project
|
N/A | |
Completed |
NCT05082142 -
Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)
|
Phase 4 | |
Completed |
NCT01260129 -
Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
|
Phase 4 | |
Completed |
NCT00771394 -
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
|
Phase 4 | |
Active, not recruiting |
NCT03630926 -
Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
|
||
Completed |
NCT02429219 -
Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate
|
N/A | |
Completed |
NCT01342562 -
The Effects of Intrathecal Dexmedetomidine on Spinal Anesthesia Using Diluted Low-Dose Bupivacaine for Transurethral Resection of Prostate in Elderly
|
N/A | |
Completed |
NCT00382356 -
Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)
|
N/A | |
Completed |
NCT00029822 -
Clinical Trial in Males With BPH (Enlarged Prostate)
|
Phase 3 | |
Completed |
NCT05308017 -
Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP
|
N/A | |
Completed |
NCT00670306 -
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Completed |
NCT00663858 -
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
|
Phase 3 | |
Terminated |
NCT00449150 -
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
|
Phase 3 | |
Completed |
NCT00037141 -
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
|
Phase 1/Phase 2 | |
Suspended |
NCT02533687 -
Comparison of Different Energy Sources During TUR-P
|
N/A | |
Completed |
NCT00427219 -
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
|
Phase 2 | |
Completed |
NCT04781049 -
Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial
|
N/A | |
Completed |
NCT02051036 -
Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study
|
N/A | |
Completed |
NCT00634608 -
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
|
N/A |